Peptide Therapeutics Market Size, Trends and Growth Analysis by 2027

The peptide therapeutics sector was valued at approximately US$ 24,878.55 million in 2019 and is anticipated to grow to US$ 50,003.15 million by 2027, reflecting a compound annual growth rate (CAGR) of 9.2% from 2020 to 2027.

This expansion in the peptide therapeutics market can be primarily attributed to increased investments in peptide-based treatments and the rising incidence of metabolic disorders and infectious diseases. Nevertheless, the operational challenges associated with peptides pose a barrier to market growth.

Ongoing research and development in peptide therapeutics have revealed their potential in addressing various chronic conditions, including renal disorders, genetic diseases, cancer, and neurodegenerative disorders. The promising results from peptide therapies are driving investments aimed at the creation of new pharmaceuticals. For example, in December 2020, Peptilogics secured approximately US$ 35.4 million in a series of funding rounds to expedite the development of its peptide therapeutic candidate, PLG0206. Additionally, in October 2020, Lassogen raised US$ 4.5 million through series funding to advance the development of lasso peptides, which are expected to provide enhanced treatment options for cancer, autoimmune diseases, pain, and inflammation. Furthermore, in December 2020, ONL Therapeutics completed a series funding round totaling US$ 46.9 million for its peptide candidate ONL1204, aimed at treating retinal diseases.

Companies are also making significant investments to broaden their presence in the peptide market. For instance, in March 2019, Creative Peptides, a US-based firm, introduced new pharmaceutical peptide services to expand the applications of peptides in drug discovery. In October 2019, UCB announced its intention to acquire RA Pharmaceuticals to enhance its peptide drug portfolio, which currently includes products in development. Such strategic investments are expected to foster growth in the peptide therapeutics market throughout the forecast period.

The increasing use of peptide molecules in the development of COVID-19 vaccines is projected to positively influence market growth. Additionally, substantial backing from government entities for the application of peptides in COVID-19 vaccine research is likely to create further opportunities for the adoption of peptides, thereby accelerating the growth of the peptide therapeutics market.

The peptide therapeutics market is categorized by type into innovative and generic peptides. The innovative segment accounted for a larger market share in 2019; however, the generics segment is expected to exhibit a higher CAGR during the forecast period.

In terms of administration routes, the peptide therapeutics market is divided into parenteral, mucosal, oral, pulmonary, and other methods. The parenteral route held the largest market share in 2019, while the oral route is projected to experience the highest CAGR in the coming years.

Regarding synthesis technology, the market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. The SPPS segment dominated the market in 2019, but the hybrid technology segment is anticipated to achieve the highest CAGR during the forecast period.

From an application perspective, the peptide therapeutics market is classified into cancer, metabolic disorders, cardiovascular diseases, respiratory issues, pain management, and dermatological conditions. The cancer segment held the largest market share in 2019, while the metabolic disorders segment is expected to register the highest CAGR in the forecast period.

Key organizations such as the World Health Organization (WHO), Food and Drug Administration (FDA), National Health Service (NHS), and Centers for Disease Control and Prevention (CDC) are among the primary and secondary sources consulted in the preparation of this report.